Abstract: A process for acid catalyzed alkylation involving the use of surfactants which form bi-continuous micro-emulsions with the liquid acid and the hydrocarbon is described. The bicontinuous phase formed between the hydrocarbon and liquid acid phases at surfactant addition facilitates and improves the liquid acid catalyzed alkylation reactions including motor-fuel alkylation reaction.

Abstract: Described herein is a method for producing a zeolite catalyst useful for aromatization of a lower alkane, a zeolite catalyst useful for aromatization of a lower alkane obtainable by said method and a process for aromatization of a lower alkane using the zeolite catalyst.

Abstract: This invention relates to processes and systems for converting acyclic hydrocarbons to alkenes, cyclic hydrocarbons and/or aromatics, for example converting acyclic C5 hydrocarbons to cyclopentadiene in a reactor system. The process includes heating an electrically-conductive reaction zone by applying an electrical current to the first electrically-conductive reaction zone; and contacting a feedstock comprising acyclic hydrocarbons with a catalyst material in the electrically-conductive reaction zone under reaction conditions to convert at least a portion of the acyclic hydrocarbons to an effluent comprising alkenes, cyclic hydrocarbons, and/or aromatics.

Abstract: A process for hydrogenation of an aromatic hydrocarbon including introducing a hydrocarbon feed comprising the aromatic hydrocarbon, a hydrogen feed comprising hydrogen, and a hydrogenation catalyst into a hydrogenation reactor operable with a liquid phase and a gas phase to produce a hydrogenation product; removing a gas phase product stream comprising the hydrogenation product; withdrawing a portion of the liquid phase; subjecting the withdrawn portion to heat exchange to provide a reduced-temperature withdrawn portion; introducing the reduced-temperature withdrawn portion back into the hydrogenation reactor; and at least one of: (a) providing at least two heat exchangers to effect the subjecting of the withdrawn portion of the liquid phase to heat exchange; (b) separating a decomposition product of the hydrogenation catalyst, the hydrogenation catalyst, or both, from the withdrawn portion of the liquid phase prior to the heat exchange; and (c) reducing exposure of the hydrogenation catalyst to an oxygen-co

Abstract: A system and a method for dehydrogenating isobutane to isobutylene are disclosed. The system comprises a fixed bed dehydrogenation reactor. The fixed reactor bed in the fixed bed dehydrogenation reactor includes a catalyst layer, a first material adapted to improve the flow distribution in the fixed reactor bed, a second material adapted to improve the thermal distribution in the fixed reactor bed, and a third material adapted to improve both the flow distribution and the thermal distribution in the fixed reactor bed. The first material covers a top, a bottom, and at least a portion of a side surface of the catalyst layer of the fixed reactor bed. The second material and the third material both are evenly distributed in the catalyst layer.

Abstract: Multi-reactor systems with aromatization reactor vessels containing a catalyst with low surface area and pore volume, followed in series by aromatization reactor vessels containing a catalyst with high surface area and pore volume, are disclosed. Related reforming methods using the different aromatization catalysts also are described.

Abstract: Apparatuses, systems and methods for separating highly pure unsaturated olefinic hydrocarbon stream with zero cooling water and or steam consumption, with minimum possible capital investment and uncompromised operational ease are disclosed herein from a mixture of hydrocarbon stream consisting of saturated and unsaturated hydrocarbons. Embodiments of the invention are directed to producing a hydrocarbon stream containing polymer, chemical grade ethylene, propylene, butylenes, isoprene, hexane stream which are of value in manufacturing chemicals, polymers, and rubbers. Embodiments of the process provided can be applied to concentrating ethylene, propylene, butylenes, cyclopentadiene, isoprene, 2 methyl butene-2, isopentane, hexene etc.

Abstract: The method according to this disclosure is a method for separating an unsaturated hydrocarbon having 2 or 3 carbon atoms and a halogenated unsaturated carbon compound formed by replacing at least one of hydrogen atoms included in the unsaturated hydrocarbon with a fluorine atom, from each other and is a method for selectively adsorbing either the unsaturated hydrocarbon or the halogenated unsaturated carbon compound by a porous coordination polymer that includes a metallic ion having a valence of 2 to 4 and an aromatic anion having 1 to 6 aromatic ring(s).

Abstract: Disclosed is a fluorination method comprising providing an aryl fluorosulfonate and a fluorinating reagent to a reaction mixture; and reacting the aryl fluorosulfonate and the fluorinating reagent to provide a fluorinated aryl species. Also disclosed is a fluorination method comprising providing , a salt comprising a cation and an aryloxylate, and SO2F2 to a reaction mixture; reacting the SO2F2 and the ammonium salt to provide a fluorinated aryl species. Further disclosed a fluorination method comprising providing a compound having the structure Ar-OH to a reaction mixture; where Ar is an aryl or heteroaryl; providing SO2F2 to the reaction mixture; providing a fluorinating reagent to the reaction mixture; reacting the SO2F2, the fluorinating reagent and the compound having the structure Ar-OH to provide a fluorinated aryl species having the structure Ar-F.

Abstract: The disclosure relates to a method for hydrofluorination of an olefin of the formula: RCX?CYZ to produce a hydrofluoroalkane of formula RCXFCHYZ or RCXHCFYZ, wherein X, Y, and Z are independently the same or different and are selected from the group consisting of H, F, Cl, Br, and C1-C6 alkyl which is partially or fully substituted with chloro or fluoro or bromo; and R is a C1-C6 alkyl which is unsubstituted or substituted with chloro or fluoro or bromo, comprising reacting the olefin with HF in the liquid-phase, in the presence of SbF5, at a temperature ranging from about ?30° C. to about 65° C. and compositions formed by the process.

Abstract: A hydrogenation process is disclosed. The process involves reacting a fluoroolefin with H2 in a reaction zone in the presence of a palladium catalyst to produce a hydrofluoroalkane product, wherein the palladium catalyst comprises palladium supported on a carrier wherein the palladium concentration is from about 0.001 wt % to about 0.2 wt % based on the total weight of the palladium and the carrier. Also disclosed is a palladium catalyst composition consisting essentially of palladium supported on ?-Al2O3 wherein the palladium concentration is from about 0.001 wt % to about 0.2 wt % based on the total weight of the palladium and the ?-Al2O3.

Abstract: Methods for chemically converting sugars or sugar alcohols into polyols/glycols, wherein the sugars or sugar alcohols are converted by means of hydrogenolysis in the presence of a catalyst comprising at least one metal and on a carbon support, wherein a nitrogen-doped carbon support is used as a catalyst support. The disclosure provides methods for chemically converting sugars or sugar alcohols into glycols which permits the preparation of glycols with higher selectivity and reduces the formation of lactic acid as a by-product.

Abstract: The present invention relates to a process for recovering 3-methylbut-3-en-1-ol from a feed stream F1 comprising 3-methylbut-3-en-1-ol, one or more solvents, water, and isobutene, wherein 3-methylbut-3-en-1-ol, the one or more solvents and water are separated from isobutene by distillation, the process comprising subjecting the feed stream F1 to distillation conditions in a distillation unit, obtaining a bottoms stream B1 which is enriched in -methylbut-3-en-1-ol, in the one or more solvents and in water compared to the feed stream F1 subjec The present invention relates to a process for recovering 3-methylbut-3-en-1-ol from a feed stream F1 comprising 3-methylbut-3-en-1-ol, one or more solvents, water, and isobutene, wherein 3-methylbut-3-en-1-ol, the one or more solvents and water are separated from isobutene by distillation, the process comprising subjecting the feed stream F1 to distillation conditions in a distillation unit, obtaining a bottoms stream B1 which is enriched in -methylbut-3-en-1-ol, in the

Abstract: A process for the production of glycolic acid or a derivative thereof comprises: reacting formaldehyde with carbon monoxide and water in a carbonylation reactor in the presence of a sulfur catalyst, said reactor operating under suitable conditions, such that glycolic acid is formed; recovering a first product stream comprising glycolic acid, impurities and a sulfur species in the carbonylation reactor; passing the first product stream to an esterification reactor where it is subjected to esterification to form an alkylglycolate and wherein the esterification is catalysed by the sulfur species recovered in the first product stream; recovering a second product stream comprising the alkylglycolate, sulfur species and impurities from the esterification reactor; separating the sulfur species from the second product stream and recycling it to the carbonylation reactor in step (a) to form a sulphur depleted second product stream; separating the alkylglycolate from the sulphur depleted second product stream in a dist

Abstract: A process for producing ethylene and acetic acid is proposed in which an ethane- and oxygen-containing reaction input stream is formed and a portion of the ethane and of the oxygen in the reaction input stream is converted into the ethylene and the acetic acid by oxidative dehydrogenation to obtain a process gas, wherein the process gas contains the unconverted portion of the ethane and of the oxygen, the ethylene and the acetic acid and also water. It is provided that the process comprises adjusting in the process gas a water partial pressure according to a specified product ratio of the acetic acid to the ethylene to a value in a range between 0.7 and 5 bar (abs.). A corresponding plant (100) likewise forms part of the subject matter of the present invention.

Abstract: The present invention relates to a novel production method of a novel prostaglandin derivative or a pharmaceutically acceptable salt thereof useful as a medicament, and an intermediate therefor. According to the present invention, a production method of a novel prostaglandin derivative or a pharmaceutically acceptable salt thereof including a conversion step from a compound represented by the following formula 3 to a compound represented by the formula 1 can be provided: wherein each symbol is as defined in the DESCRIPTION.

Abstract: Methylene-cycloalkylacetate compounds and derivatives thereof and their use in methods for treatment of neurotropic conditions.

Abstract: In a method for producing an aliphatic carboxylic acid ester by reacting an aliphatic carboxylic acid having from 1 to 5 carbon atoms and an olefin having from 2 to 4 carbon atoms in a gas phase by use of a solid acid catalyst, a solid acid catalyst in which a heteropolyacid or a salt thereof is supported on a silica carrier obtainable by kneading fumed silica obtained by a combustion method, silica gel obtained by a gel method, and colloidal silica obtained by a sol-gel method or a water glass method, molding the resulting kneaded product, and calcining the resulting molded body, is used.

Abstract: A process for continuously preparing a butyl acrylate H2C?CH—C(?O)OR, with R=n-butyl or isobutyl, wherein aqueous 3-hydroxypropionic acid is converted under dehydrating and esterifying conditions in the presence of the corresponding butanol R—OH in a reactor with a rectification column and butyl acrylate formed, unconverted butanol and water used and formed are distilled off overhead as a ternary azeotrope, after separation into a liquid aqueous phase and liquid organic phase each of the aqueous and organic phases is at least partly discharged, and the organic phase comprising the butyl acrylate and the butanol is subjected to distillative separation.

Abstract: A method for directly producing methyl acetate and/or acetic acid from syngas, carried out in at least two reaction zones, including: feeding a raw material containing syngas into a first reaction zone to contact and react with a metal catalyst; allowing an obtained effluent to enter a second reaction zone directly or after the addition of carbon monoxide so as to contact and react with a solid acid catalyst; separating the obtained effluent to obtain product of acetate and/or acetic acid, and optionally returning a residual part to enter the first reaction zone and/or the second reaction zone to recycle the reaction. This provides a novel method for directly converting syngas into methyl acetate and/or acetic acid. Further, the product selectivity of the product of methyl acetate or acetic acid is greater than 93%, and the quantity of methyl acetate and acetic acid may be adjusted according to processing.

Abstract: The present application addresses the problem of providing a method for efficiently producing a dialkyl carbonate. The problem can be solved by a method for producing a dialkyl carbonate by reacting urea and at least one alkyl carbamate with an aliphatic alcohol in the presence of a catalyst, the method including introducing a gas for expelling ammonia generated by the reaction into a reactor in which the reaction is being conducted and discharging the ammonia generated in the reactor and the introduced gas, the reaction being conducted so that the gas introduction satisfies relationship (1). 52.0<((A+B)×22400+L×M/17.03×22400)/L<91.0??(1) (In formula (1), A, B, L, and M are as defined above.

Abstract: A compound of formula (I): wherein W is independently selected from the group consisting of H, F, Cl, Br, and I; X is independently selected from the group consisting of H, F, Cl, Br, and I; Y is independently selected from the group consisting of F, Cl, Br, and I; Z is independently selected from the group consisting of H, F, Cl, Br, and I; n is an integer from 1 to 8; and n? is an integer from 1 to 12.

Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.

Abstract: The present disclosure encompasses a composition comprising three-dimensional shapes, wherein each shape consists essentially of choline chloride, and methods of making such three-dimensional shapes.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: The present invention relates to a process for synthesis of a compound according to Formula (A): wherein R1 is a substituted or unsubstituted aryl having 6 to 20 carbon atoms; preferably substituted or unsubstituted phenyl; R2 is a straight or branched alkyl having 1 to 12 carbon atoms; and R3 is a straight or branched alkyl having 1 to 12 carbon atoms; starting from a di-keto compound according to Formula (B) wherein R3 is as shown above, which compound is converted into a ketoenamine compound according to Formula (C) wherein R2 and R3 are as shown above, which ketoenamine compound is then reduced to an amino alcohol according to Formula (D), wherein R2 and R3 are as shown above, that is subsequently converted into a compound according to Formula (A): characterized in that the ketoenamine is reduced into an amino alcohol using a nickel aluminium alloy in an aqueous solution of an inorganic base.

Abstract: A process for producing cyanonorbornene of the present invention includes Step 1 of preparing a mixture solution including 0.5% by weight to 28% by weight of methyl bicyclononadiene, with respect to a total amount of 100% by weight of dicyclopentadiene, acrylonitrile, and the methyl bicyclononadiene, in a container, and Step 2 of reacting the bicyclopentadiene with the acrylonitrile in the presence of the methyl bicyclononadiene, in the mixture solution.

Abstract: A method is provided to purify [F-18]FEONM under a high pressure. The synthesis processes of [F-18]FEONM are integrated. An isolation process of non-toxic radio-high performance liquid chromatography (radio-HPLC) is used to purify the crude product. The method integrates a convention [F-18]FDG synthesizer and a novel radio-HPLC system together in a heat chamber. After radiofluorinating the precursor, the reaction product is purified with an alumina solid-phase column in advance to obtain the crude product while fluorine-18 is removed. Then, diphenyl semipreparative HPLC column is used for a final purification. A non-toxic solvent is used for mobile-phase eluting to remove the unreacted precursor and the phase-transfer solvent. The radiofluorination has a reaction yield about 50 percent (%). The method has an uncorrected radiochemical yield of 10˜20%. Both of the radio-HPLC and the radio-thin layer chromatography (radio-TLC) have radiochemical purity higher than 95%.

Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Abstract: The present disclosure discloses a biaryl urea ROR?t inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an ROR?t inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an ROR?t-related disease.

Abstract: Dehydroabietic acid derivatives according to Formula Ia or Formula Ib and all stereoisomers thereof, having a linker chain A of 1 to 10 atoms selected from carbon, nitrogen and oxygen to a group X capable of being negatively charged at a physiological pH and covalently attached to the linker chain A, selected from carboxyl, sulfate, sulfonate and phosphate groups.

Abstract: The present invention relates to thermotropic ionic liquid crystal molecules of general formula (I) With E1 and E2, which may be identical or different, representing, independently of one another, a linear, saturated and unsubstituted C10 to C14 hydrocarbon-based radical, Ax? representing a sulfonate anion or a sulfonylimide anion of formula —SO2—N?—SO2CyF2y+1 with y being an integer ranging from 0 to 2 and Cx+ a sodium, lithium or potassium ion, most particularly advantageous for their conductivity performance qualities as an electrolyte in particular for lithium batteries.

Abstract: A process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol including the following steps: a) the reaction of a solution of amifostine with a strong acid, to obtain a solution of 2-[(3-aminopropyl)amino]ethanethiol, and b) the freeze-drying of the solution of 2-[(3-aminopropyl)amino]ethanethiol, with or without addition of excipients.

Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).

Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.

Abstract: A compound of formula (I), or an N-oxide thereof is provided. In the compound of formula (I), Het1 represents Het1-1, Het1-2, Het1-3, Het1-4, Het1-5, Het1-6, Het1-7, Het1-8, or Het1-9, and the remaining variable groups are as defined in the specification. The compound of formula (I), or N-oxide thereof has a superior effect in controlling arthropod pests.

Abstract: An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)?(D-TA): in which p represents an integer of 0 to 4; R1 each independently represent a halogen atom, a cyano group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a hydroxy C1-6 alkyl group, a cyanated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkyl group, a mono-/di-C2-7 alkanoyl amino group, a carboxamide group, or a C1-6 alkoxy carbonyl group; and R2a and R2b each independently represent a C1-6 alkyl group.

Abstract: Provided are IDO1 inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.

Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Abstract: The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Provided is a method for producing a 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, which is suitable for the production on an industrial scale. The present invention provides: a method for producing an intermediate for the production of a 2-alkylcarbonyl[2,3-b]furan-4,9-dione, which comprises reacting a 1-butyne derivative in which a ketone or an alcohol is protected with a 2-hydroxy-1,4-naphthoquinone derivative having a leaving group at position-3 in a solvent in the presence of a metal or a metal compound and a base; and a substance relating to the intermediate.

Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.

Abstract: The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.

Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Abstract: The disclosure provides methods and compositions for providing shatter formulations taking the form of crystalline polymorphs, where methods of preparation include preparing tetrahydrocannabinol acid (THCA) powder followed by decarboxylating THCA and removal of terpenes.

Abstract: The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.

Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitinization of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.